LUNDBECK NA LTD
PharmaLUNDBECK NA LTD is a pharmaceutical company focused on Neurology. Key products include NORTHERA.
LUNDBECK NA LTD's Key Drugs
LUNDBECK NA LTD's core commercial portfolio centers on NORTHERA, spanning Neurology — its most strategically important drugs approved in the last 15 years.
LUNDBECK NA LTD's Recent FDA Approvals
New NDA/BLA approvals for LUNDBECK NA LTD over the last two years — novel drugs only, excluding generics and label supplements.
LUNDBECK NA LTD's Therapeutic Areas
LUNDBECK NA LTD's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
LUNDBECK NA LTD's Top Competitors
LUNDBECK NA LTD's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
LUNDBECK NA LTD Pipeline Snapshot
Active clinical trials for LUNDBECK NA LTD across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2014-02-18
- Latest
- 2017-02-10
- Applications
- 1